Loading organizations...

§ Private Profile · Shenzhen, Guangdong, China
Biotechnology company developing autonomous equipment for cell and gene therapy, focused on cancer immunotherapy and manufacturing.
EurekaBio is a biotechnology hardware and software developer based in Shekou, Shenzhen, China, that engineers autonomous equipment specifically designed for cell and gene therapy manufacturing. The organization operates as an upstream core supplier for the broader medical sector, integrating artificial intelligence, automation, and interdisciplinary engineering to advance global cancer immunotherapy treatments. By providing specialized technical infrastructure, the firm addresses complex production bottlenecks encountered during gene therapy, cell therapy, life sciences, and commercial pharmaceutical research and development. While specific funding totals, financial valuation metrics, and enterprise customer lists are not currently disclosed, the company utilizes foundational biological and engineering research associated with the Hong Kong University of Science and Technology (HKUST). EurekaBio was officially established in 2014 by a group of three founding partners, which prominently includes former HKUST alumni Mo Ma and Xue Bofu.
EurekaBio has raised $40.0M across 1 funding round.
EurekaBio has raised $40.0M in total across 1 funding round.
EurekaBio has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 7, 2024 | $40M Series B | — | — | Announced |
EurekaBio has raised $40.0M in total across 1 funding round.